Literature DB >> 11441998

Thyroid-infiltrating B lymphocytes in Graves' disease are related to marginal zone and memory B cell compartments.

C Segundo1, C Rodríguez, A García-Poley, M Aguilar, I Gavilán, C Bellas, J A Brieva.   

Abstract

B lymphocytes that infiltrate the thyroid (Thy-B cells) in Graves' patients appear to be implicated in the pathophysiology of this disorder. The goal of the present study was to examine the nature of these Thy-B cells. To this end, Thy-B lymphocytes were isolated from surgical thyroidal samples, and their phenotype was determined by using mouse monoclonal antibodies (mAb) directed against a wide variety of surface markers, followed by flow cytometry multicolor analysis. The results show that most Thy-B cells (approximately 60%) exhibited IgM(+) IgD(low to -) surface immunoglobulin (Ig) profile, whereas the minor cell fraction (approximately 30%) consisted of switched IgG(+) memory B lymphocytes. Thy-B cells expressed low levels of CD5, CD23, and CD62L, which distinguished them from the resting B-cell pool, the major B-cell subset in the blood. In addition, they lacked CD38, CD10, and CD71, characteristic molecules for the germinal center B lymphocytes. In addition, Thy-B lymphocytes showed peculiar patterns both of adhesion molecules (CD62L(-), CD44(intermediate)), and of activation molecules (CD69(+), CD80(+), and, in part, CD95(+)). Taken together, these results suggest that the Thy-B lymphocyte subset consists of a combination of IgM(+) B cells resembling marginal zone B lymphocytes, and isotype-switched memory B cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11441998     DOI: 10.1089/105072501750302813

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  7 in total

1.  A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys.

Authors:  Yulia Vugmeyster; Dhaya Seshasayee; Wesley Chang; Anahid Storn; Kathy Howell; Susan Sa; Tenea Nelson; Flavius Martin; Iqbal Grewal; Ellen Gilkerson; Ben Wu; Jeff Thompson; Barbara N Ehrenfels; Song Ren; An Song; Thomas R Gelzleichter; Dimitry M Danilenko
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

2.  Lymphocytes in peripheral blood and thyroid tissue in children with Graves' disease.

Authors:  Ben-Skowronek Iwona; Sierocinska-Sawa Jadwiga; Korobowicz Elzbieta; Szewczyk Leszek
Journal:  World J Pediatr       Date:  2008-12-23       Impact factor: 2.764

3.  The peripheral blood compartment in patients with Graves' disease: activated T lymphocytes and increased transitional and pre-naive mature B lymphocytes.

Authors:  K Van der Weerd; P M Van Hagen; B Schrijver; D J Kwekkeboom; W W De Herder; M R J Ten Broek; P T E Postema; J J M Van Dongen; F J T Staal; W A Dik
Journal:  Clin Exp Immunol       Date:  2013-11       Impact factor: 4.330

Review 4.  B cell depletion in autoimmune diabetes: insights from murine models.

Authors:  Jayne L Chamberlain; Kesley Attridge; Chun Jing Wang; Gemma A Ryan; Lucy Sk Walker
Journal:  Expert Opin Ther Targets       Date:  2011-03-03       Impact factor: 6.902

5.  Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves' ophthalmopathy.

Authors:  P Bonara; G Vannucchi; I Campi; S Rossi; F Cantoni; C Frugoni; F Sbrozzi; C Guastella; S Avignone; P Beck-Peccoz; M Salvi
Journal:  Clin Rev Allergy Immunol       Date:  2008-02       Impact factor: 8.667

6.  CD19 regulates ADAM28-mediated Notch2 cleavage to control the differentiation of marginal zone precursors to MZ B cells.

Authors:  Yu Zhang; Gaizhi Zhu; He Xiao; Xiaoling Liu; Gencheng Han; Guojiang Chen; Chunmei Hou; Beifen Shen; Yan Li; Ning Ma; Renxi Wang
Journal:  J Cell Mol Med       Date:  2017-07-14       Impact factor: 5.310

Review 7.  Thymic B Cells as a New Player in the Type 1 Diabetes Response.

Authors:  Richard B Greaves; Dawei Chen; E Allison Green
Journal:  Front Immunol       Date:  2021-10-21       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.